[关键词]
[摘要]
目的 探讨康妇炎胶囊联合头孢噻肟钠治疗子宫内膜炎的临床疗效。方法 选取2018年5月-2019年5月在眉山市人民医院治疗的子宫内膜炎患者84例,根据用药的差别分为对照组(42例)和治疗组(42例)。对照组静脉滴注注射用头孢噻肟钠,2.0 g/次加入生理盐水100 mL,2次/d;治疗组在对照组基础上口服康妇炎胶囊,1.2 g/次,3次/d。两组均治疗2周。观察两组患者临床疗效,同时比较治疗前后两组患者临床症状积分,GQOLI-74、FSFI和VAS评分,及血清C反应蛋白(CRP)、白细胞介素-4(IL-4)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)和基质金属蛋白酶-2(MMP-2)水平。结果 治疗后,对照组临床有效率为80.95%,显著低于治疗组的97.62%,两组比较差异具有统计学意义(P<0.05)。经治疗,两组患者症状评分均显著下降(P<0.05),且治疗组比对照组下降更明显(P<0.05)。经治疗,两组患者GQOLI-74评分明显升高(P<0.05),而FSFI和VAS评分均明显降低(P<0.05),且治疗组GQOLI-74、FSFI和VAS评分明显好于对照组(P<0.05)。经治疗,两组患者血清CRP、IL-4、IL-8、TNF-α、MMP-9水平均显著降低(P<0.05),且治疗组患者明显低于对照组(P<0.05)。结论 康妇炎胶囊联合注射用头孢噻肟钠治疗子宫内膜炎患者可有效改善患者临床症状,降低机体炎症反应,提高患者性生活质量,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To explore the clinical efficacy of Kangfuyan Capsules combined with cefotaxime sodium in treatment of endometritis. Methods Patients (84 cases) with endometritis in Meishan People's Hospital from May 2018 to May 2019 were divided into control (42 cases) and treatment (42 cases) groups based on different treatments. Patients in the control group were iv administered with Cefotaxime Sodium for injection, 2 g added into normal saline 100 mL, twice daily. Patients in the treatment group were po administered with Kangfuyan Capsules on the basis of the control group, 1.2 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom score, the GQOLI-74, FSFI and VAS score, and the serum level of CRP, IL-4, IL-8, TNF-α, and MMP-2 in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 80.95%, which was significantly lower than 97.62% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the clinical symptom score in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the GQOLI-74 score in two groups was significantly increased (P<0.05), but the FSFI and VAS score was significantly decreased (P<0.05), and the GQOLI-74, FSFI and VAS score in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the serum level of CRP, IL-4, IL-8, TNF-α and MMP-2 in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Kangfuyan Capsules combined with cefotaxime sodium in treatment of endometritis can effectively improve the clinical symptoms, reduce inflammation and improve the quality of sexual life, which has a certain clinical application value.
[中图分类号]
R984
[基金项目]
四川省卫生和计划生育委员会科研项目(18PJ068)